Rivia is a technology company building a data engine that powers the future of clinical trial intelligence. Rivia was founded on the belief that new drugs can be brought to market more successfully with a fraction of today's capital.

Biotechs are the source of most therapeutic innovation, yet clinical development is constantly constrained by fragmented data and outdated tooling. Rivia unifies clinical trial data at scale through a core engine built as a reusable intelligence layer, comprising hundreds of configurations and trial-specific logic, independent of source structure. This vertical stack of data engine, workflows, and agents creates a distinct advantage in how trials are operated.

Over the past two years, European and US based biotechs running global clinical trials on Rivia have demonstrated measurable impact, from earlier understanding of therapeutic potential to significantly more efficient trial execution. In March 2026, Rivia raised its $15M Series A l...